Literature DB >> 11085587

Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.

C C Tsai1, P Emau, J C Sun, T W Beck, C A Tran, K E Follis, N Bischofberger, W R Morton.   

Abstract

We report that simian immunodeficiency virus (SIV) infection in macaques is a valuable animal model for studying post-exposure chemoprophylaxis (PECP). PECP with the acyclic nucleoside reverse transcriptase inhibitors 9-(2-phosphonylmetho-xyethyl)adenine (PMEA) and (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) at early viral infection can provide long-term protection against subsequent heterologous SIV challenge. Eight macaques previously treated with PECP (called PECP macaques) and four naive controls were challenged intravenously with the most virulent form of SIV, SIV(PBj14). All controls showed signs of SIV(PBj14)-induced acute disease syndrome on days 6 and 7 post-inoculation (PI). One had a fatal viral infection and two surviving controls had persistent infection and decreased CD4+ cell count. Virologic studies of the three surviving controls revealed SIV in multiple lymphoid tissues and peripheral blood mononuclear cells (PBMCs) at necropsy. In contrast, the PECP macaques showed none to mild signs of acute disease syndrome at day 9 PI and exhibited only transient SIV infection in PBMCs between weeks 1 and 8 PI. In virologic studies of five PECP macaques necropsied, two macaques were SIV-negative and the other three were SIV-positive only in either lymph node or bone marrow. Three SIV(PBj14)-challenged PECP macaques, that were randomly reserved for a follow-up study for > 4.0 years PI showed extremely low to undetectable levels of PBMC-associated viremia and normal to increased levels of CD4 + and CD8 + cell counts throughout the study. Our results indicate that early PECP could activate immune responses to protect against subsequent infection with heterologous challenge virus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085587     DOI: 10.1034/j.1600-0684.2000.290318.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  8 in total

1.  Development of guidelines on nonoccupational HIV postexposure prophylaxis for the state of Rhode Island.

Authors:  Roland C Merchant; Kenneth H Mayer; Carol A Browning
Journal:  Public Health Rep       Date:  2004 Mar-Apr       Impact factor: 2.792

Review 2.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 3.  Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?

Authors:  Wenya Yu; Lu Wang; Na Han; Xiayan Zhang; Tanmay Mahapatra; Sanchita Mahapatra; Giridhar R Babu; Weiming Tang; Roger Detels; Jinkou Zhao
Journal:  Artif Cells Nanomed Biotechnol       Date:  2014-07-31       Impact factor: 5.678

Review 4.  AIDS vaccines and preexposure prophylaxis: is synergy possible?

Authors:  Jean-Louis Excler; Wasima Rida; Frances Priddy; Jill Gilmour; Adrian B McDermott; Anatoli Kamali; Omu Anzala; Gaudensia Mutua; Eduard J Sanders; Wayne Koff; Seth Berkley; Patricia Fast
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-16       Impact factor: 2.205

5.  Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.

Authors:  Gaudensia Mutua; Eduard Sanders; Peter Mugo; Omu Anzala; Jessica E Haberer; David Bangsberg; Burc Barin; James F Rooney; David Mark; Paramesh Chetty; Patricia Fast; Frances H Priddy
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

6.  Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention.

Authors:  Peter Emau; Yonghou Jiang; Michael B Agy; Baoping Tian; Girma Bekele; Che-Chung Tsai
Journal:  AIDS Res Ther       Date:  2006-11-28       Impact factor: 2.250

7.  Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.

Authors:  Paul W Denton; John F Krisko; Daniel A Powell; Melissa Mathias; Youn Tae Kwak; Francisco Martinez-Torres; Wei Zou; Deborah A Payne; Jacob D Estes; J Victor Garcia
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

8.  Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL.

Authors:  Maria S Salvato; C Cameron Yin; Hideo Yagita; Toshihiro Maeda; Ko Okumura; Ilia Tikhonov; C David Pauza
Journal:  Clin Dev Immunol       Date:  2007
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.